Table 6 Health technology assessment information deemed to be important by stakeholders by country (scale responses: 1 = strongly disagree; 7 = strongly agree)

Prevalence of smoking

28

5.89 (1.34)

16

6.38 (1.41)

17

5.82 (1.55)

18

5.78 (1.96)

14

5.64 (2.41)

93

5.90 (1.69)

0.38

Costs of smoking

28

6.29 (0.85)

16

7.00 (0.00)

17

6.53 (0.62)

18

6.28 (1.41)

14

6.71 (1.07)

93

6.52 (0.94)

0.002

Quality of life

28

5.79 (1.32)

16

6.13 (1.26)

17

5.41 (1.87)

18

6.06 (1.39)

14

5.86 (1.10)

93

5.84 (1.40)

0.63

Mortality due to smoking

28

6.11 (1.26)

16

6.75 (1.00)

17

5.88 (1.93)

18

6.33 (1.03)

14

6.64 (1.34)

93

6.30 (1.35)

0.010

Effectiveness of smoking cessation interventions (such as quit and relapse rates)

28

6.39 (1.20)

16

6.50 (1.27)

17

6.18 (1.67)

18

6.39 (1.42)

14

6.71 (1.07)

93

6.42 (1.31)

0.35

Cost-effectiveness data comparing the cost of smoking cessation interventions with its health and wider benefits

28

6.43 (0.88)

16

6.69 (0.48)

17

6.18 (1.02)

18

6.78 (0.43)

14

6.86 (0.36)

93

6.56 (0.74)

0.093

Budget impact reflecting financialoutcomes specifically at organisational level

28

6.07 (1.25)

16

6.69 (0.60)

17

6.00 (1.37)

18

6.67 (0.49)

14

6.00 (1.47)

93

6.27 (1.13)

0.17